Fenbendazole is an anthelmintic drug that has been used to treat parasitic worm infections in dogs since the early 1970s.
However, there have been multiple published and peer-reviewed articles with case reports demonstrating that fenbendazole is also quite successful in the treatment of various aggressive malignancies in people in recent years. This is thought to be due to the following distinct advantages of fenbendazole over other cancer-fighting medications:
- As previously said, there are several scientific articles that support and confirm its efficacy in treating various aggressive tumors in people.
E.g. Fenbendazole alone has been shown to be a successful therapy for producing tumor regression in people with diffuse large B-cell lymphoma (Source), metastatic cancer, renal cell carcinoma, and bladder cancer.
- Fenbendazole has few adverse effects and is quite safe to use in people.
- In many countries, it is accessible without a prescription.
- It is incredibly cheap to manufacture.
We found that the anticancer effect of fenbendazole is remarkably comparable to the plant alkaloids category of chemotherapies, which includes the anticancer medication Taxol. Furthermore, fenbendazole’s toxicity levels are significantly lower than those reported in traditional chemotherapies owing to the unique manner it acts and its remarkable safety profile.
Many observations and studies have shown (with the appearance of specific patterns) that the genesis of various cancers may be tied to and caused by viruses, parasites, and the like.
Indeed, it is probable that this is the case in many more cases than we are aware of, particularly if the cancer cells find themselves in “fertile ground,” which is represented by weakened immunity mixed with certain genetic predispositions.
As a result, we seriously consider using anti-parasitic, anti-worm, anti-lactate, and other medications as part of a holistic cancer therapy strategy that may also include conventional cancer treatments.
- Fenbendazole may be taken by humans.
- Human use of fenbendazole
Fenbendazole, unlike mebendazole, is not a medicine that is often used in treating people. Fenbendazole is often used to treat parasitic worms in animals (including mammals, birds, and fish). It is known to kill a variety of parasitic worms including whip worm, hookworm, certain tapeworms, and roundworm.
Fenbendazole, sold under brand names such as Panacur or Safe-Guard, was originally brought to our notice in regard to cancer therapy years ago via our own study. However, it has lately regained our attention because of the well-known tale of a guy who successfully cured his small cell lung cancer with anti-worm medicine.
Since then, a dedicated website and a Facebook group have served as a platform to chronicle his own experience, as well as the experiences of other patients who are benefiting from Fenbendazole in treating cancers such as non-small cell lung cancer, melanoma, colorectal cancer, prostate cancer, stage four pancreatic cancer, and others.
These current results merely add to the existing and growing scientific data demonstrating the cancer-fighting potential of various medicines in the benzimidazole family of chemicals. As a result, we believe that similar to mebendazole, fenbendazole for humans has a strong cancer-fighting potential.
Fenbendazole For humans
In fact, in certain investigations, fenbendazole was shown to be more effective than mebendazole. In one such trial, for example, fenbendazole was shown to be much more effective than mebendazole and other medications in combating Cryptococcus neoformans – an opportunistic fungus that may be found everywhere in the globe and can cause Cryptococcus meningitis in certain individuals. (Source)
Furthermore, among the numerous scientific publications that have been published and stated that Fenbendazole has cancer-fighting qualities, this report concluded that: Fenbendazole functions as a mild microtubule destabilizing agent and promotes cancer cell death by altering various cellular pathways.
- “These findings, together with our previous findings, suggest that Fenbendazole is a new microtubule interfering agent with an anti-neoplastic activity that may be investigated as a potential therapeutic agent due to its effect on multiple cellular pathways leading to the effective elimination of cancer cells.”
The scientists found that fenbendazole’s cancer-fighting mechanisms impaired cancer cells’ proteasomal interference and microtubule activity and demonstrated the capacity to impede glucose absorption, therefore starving the cancer cells. Fenbendazole inhibited glucose transporter isoform 4 expression (GLUT4). Insulin stimulates glucose absorption in cells, transporting GLUT4 via intracellular vesicles to the plasma membrane, where it may absorb glucose. GLUT4 mobility is reduced by interrupting its linear migration via the microtubule with fenbendazole, which dramatically lowers insulin-stimulated sugar absorption.
Furthermore, while fenbendazole operates similarly to colchicine (interacting with a location on tubulin) while being unique from other vinca alkaloids, it will not compete with them or other chemotherapies. Rather, like other benzimidazole compounds, fenbendazole will increase the anti-cancer effects of other cancer treatments such as surgery, radiation, sodium dichloroacetate (DCA), berberine, and so on.
In addition, a newly released scientific article suggests that fenbendazole (and comparable medications) may be able to reactivate the genome p53. p53 is regarded as the Guardian of the Genome because it functions as a tumor suppressor. However, in certain malignancies, its suppressing capacity may be impaired.